Interictal epileptiform discharges in calcified neurocysticercosis–associated epilepsy: An exploratory study
Epilepsia · 2026
DOI: 10.1002/epi.70314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Sofia S Sanchez-Boluarte und 8 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Department, Instituto Nacional de Ciencias Neurológicas, Lima, Peru. Hauptthemen laut MEDLINE: Neurocysticercosis, Calcinosis, Epilepsy. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The objective of the study was to assess the frequency of interictal epileptiform discharges (IEDs) in calcified neurocysticercosis (NCC) and its relationship with calcification burden. Forty‐nine patients with calcified NCC (low‐burden, 1–2 calcifications, n = 24; high‐burden, ≥15 calcifications, n = 25) and seizure history underwent prolonged (8‐h) electroencephalography (EEG), interpreted by epileptologists who were blinded to patient history and calcification category. Clinical seizure outcomes were also assessed. We found that IEDs occurred in 7 of 49 participants (14.3%), with no difference between low‐burden (12.5%) and high‐burden (16.0%) groups ( p = 1.000). All IEDs (spikes and/or sharp waves) in the high‐burden group ( n = 4) were high‐voltage (100–150 μV), whereas those in the low‐burden group ( n = 3) were low or medium voltage (20–70 μV). Among the participants who had IEDs, 5 (71.4%) had seizures in the last year, compared with 14 (33.3%) in the group without IEDs detected ( p = 0.093). Among 19 participants with seizures in the last year, 5 were identified as having drug‐resistant epilepsy (DRE). All five cases of DRE occurred in individuals with 15 or more calcifications (5/25, 20%, vs 0/24, p = 0.023). We conclude that IEDs occur frequently in individuals with calcified NCC. Although calcification burden itself was not associated with the presence of IEDs, drug‐resistant cases and high‐voltage IEDs were concentrated in the high‐burden group, supporting the role of calcified parasites as epileptogenic foci.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epilepsy Department, Instituto Nacional de Ciencias Neurológicas, Lima, Peru.
- Neurosciences, Epidemiology and Global Health Research Group, Universidad Cesar Vallejo, Lima, Peru.
- Faculty of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Cysticercosis Unit, Instituto Nacional de Ciencias Neurológicas, Lima, Peru.
- Center for Global Health, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Sofia S Sanchez-Boluarte, Liza N Nuñez Del Prado, Denisse Chacon, Marlene Huamani, Betsabé Callupe-Luna, Javier A Bustos, William O Tatum, Hector H Garcia
Förderung
- FIC NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Sanchez-Boluarte, S. S., Nuñez Del Prado, L. N., Chacon, D., Huamani, M., Callupe-Luna, B., Bustos, J. A., Tatum, W. O., Garcia, H. H., & Cysticercosis Working Group in Peru (2026). Interictal epileptiform discharges in calcified neurocysticercosis–associated epilepsy: An exploratory study. Epilepsia. https://doi.org/10.1002/epi.70314
Vancouver
Sanchez-Boluarte SS, Nuñez Del Prado LN, Chacon D, Huamani M, Callupe-Luna B, Bustos JA, et al. Interictal epileptiform discharges in calcified neurocysticercosis–associated epilepsy: An exploratory study. Epilepsia. 2026. doi:10.1002/epi.70314
BibTeX
@article{SanchezBoluarte2026,
author = {Sanchez-Boluarte, Sofia S and Nuñez Del Prado, Liza N and Chacon, Denisse and Huamani, Marlene and Callupe-Luna, Betsabé and Bustos, Javier A and Tatum, William O and Garcia, Hector H and Cysticercosis Working Group in Peru, Cysticercosis Working Group in Peru},
title = {Interictal epileptiform discharges in calcified neurocysticercosis–associated epilepsy: An exploratory study},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70314}
}
EUVIMED